clinical trial · NCT06788652
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·—·recruiting·n = 300
Mantle Cell Lymphoma (MCL)Lisocabtagene maraleucel
brief summary
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
started
Feb 4, 2025
primary completion
Sep 30, 2044
completion
Sep 30, 2044
last updated
Feb 24, 2025
official title
Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol